Nanalysis Scientific (NSCI) Q2 2025 (Q&A) earnings summary

Executive summary

• Second quarter 2025 financial results were disappointing, with revenue of $9,576, down 17% year-over-year, mainly due to lower product sales amid global economic uncertainty and tariff risks.

• Security services revenue increased 7% year-over-year, partially offsetting the decline in product sales.

• Optimism at the start of 2025 was based on a strong Q4 2024 and a full sales pipeline, but market uncertainty led to stalled orders.

• Cost reduction and efficiency measures improved gross margins in the scientific equipment business, with ongoing restructuring and right-sizing efforts for sustainable profitability.

• The company remains focused on vertical integration, advancing Benchtop NMR platforms, and operational efficiency.

Financial highlights

• Six-month revenue ended June 30, 2025, was $20,170, down 11% year-over-year, with product sales down 31% and security services revenue up 7%.

• Gross margin on product sales improved to 64% for the first half of 2025, up from 49% in 2024.

• Services segment showed sequential improvement in gross margins quarter-over-quarter.

• Adjusted EBITDA loss for Q2 2025 was ($462), compared to a profit of $759 in Q2 2024; six-month Adjusted EBITDA loss was ($282) versus $655 last year.

• Net loss for Q2 2025 was $2,122, $127 higher than Q2 2024; six-month net loss was $3,429, an improvement from $4,517 in 2024.

Outlook and guidance

• Confidence expressed for a strong second half of 2025, with expectations of a good third quarter as stalled orders resume.

• Management expects continued margin improvement in security services due to process and logistics enhancements.

• The sales funnel remains solid, but economic and tariff risks may continue to impact capital equipment purchases.

• Focus remains on efficiency, margin improvement, and advancing core product and service offerings.

• Anticipated continued improvement in gross margins, especially if supply chain cost reductions are realized.